GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Cyclically Adjusted FCF per Share

Aevi Genomic Medicine (Aevi Genomic Medicine) Cyclically Adjusted FCF per Share : $0.00 (As of Sep. 2019)


View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aevi Genomic Medicine's adjusted free cash flow per share for the three months ended in Sep. 2019 was $-0.047. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-05-16), Aevi Genomic Medicine's current stock price is $0.1659. Aevi Genomic Medicine's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2019 was $0.00. Aevi Genomic Medicine's Cyclically Adjusted Price-to-FCF of today is .


Aevi Genomic Medicine Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Aevi Genomic Medicine's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Cyclically Adjusted FCF per Share Chart

Aevi Genomic Medicine Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aevi Genomic Medicine Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aevi Genomic Medicine's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Aevi Genomic Medicine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aevi Genomic Medicine's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's Cyclically Adjusted Price-to-FCF falls into.



Aevi Genomic Medicine Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aevi Genomic Medicine's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2019 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.047/108.3294*108.3294
=-0.047

Current CPI (Sep. 2019) = 108.3294.

Aevi Genomic Medicine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200912 0.000 91.111 0.000
201003 0.011 91.821 0.013
201006 -0.311 91.962 -0.366
201009 -0.245 92.162 -0.288
201012 -0.370 92.474 -0.433
201103 -0.294 94.283 -0.338
201106 -0.176 95.235 -0.200
201109 -0.263 95.727 -0.298
201112 -0.268 95.213 -0.305
201203 -0.246 96.783 -0.275
201206 -0.198 96.819 -0.222
201209 -0.128 97.633 -0.142
201212 -0.224 96.871 -0.250
201303 -0.182 98.209 -0.201
201306 -0.189 98.518 -0.208
201309 -0.119 98.790 -0.130
201312 -0.240 98.326 -0.264
201403 -0.213 99.695 -0.231
201406 -0.155 100.560 -0.167
201409 -0.104 100.428 -0.112
201412 -0.177 99.070 -0.194
201503 -0.328 99.621 -0.357
201506 -0.142 100.684 -0.153
201509 -0.210 100.392 -0.227
201512 -0.232 99.792 -0.252
201603 -0.278 100.470 -0.300
201606 -0.297 101.688 -0.316
201609 -0.173 101.861 -0.184
201612 -0.200 101.863 -0.213
201703 -0.287 102.862 -0.302
201706 -0.211 103.349 -0.221
201709 -0.173 104.136 -0.180
201712 -0.151 104.011 -0.157
201803 -0.122 105.290 -0.126
201806 -0.121 106.317 -0.123
201809 -0.075 106.507 -0.076
201812 -0.116 105.998 -0.119
201903 -0.079 107.251 -0.080
201906 -0.054 108.070 -0.054
201909 -0.047 108.329 -0.047

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Aevi Genomic Medicine  (NAS:GNMX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aevi Genomic Medicine Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Executives
Michael F Cola director, officer: Chief Executive Officer 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil officer: Chief Scientific Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca 10 percent owner 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper officer: CFO & Corporate Secretary C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum officer: Chief Legal Officer C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman officer: Chief Financial Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio officer: Chief Operating Officer 435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087